You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on prostate cancer.
In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.
Palmetto proposes to cover the assay for prostate cancer patients who are at very low and low risk of negative outcomes with active surveillance by NCCN guidelines.
The final LCD, which expands Medicare coverage of the firm's ConfirmMDx test to all providers, becomes effective on Sept. 3.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
One study characterized an allele linked to aggressive prostate cancer, while the other explored the range of structural variations within metastatic disease.
The work is being funded with $26.5 million from the 21st Century Cures Cancer Moonshot Initiative.
Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.